# The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure

> **NCT02489864** · PHASE4 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Hepatorenal Syndrome

## Interventions

- **DRUG:** Terlipressin

## Key facts

- **NCT ID:** NCT02489864
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2017-07
- **Final completion:** 2017-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2015-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489864, "The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02489864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*